Skip to Content
Søk Menu

Analysis of the cost- effectivenes of novel antiandrogens treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC)

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Implementation of Early Specialized Palliative Care in an Oncologic Department

/ Katrine Rahbek Schønnemann / Sabine Ute Alice Gill
Kreft
Petter Brandal

Insights from Onkologisk Forum 2023

/ Petter Brandal
KreftOnkologiskForum23 Play the Video 5:16
Bettina Kulle Andreassen

The Value of Real-World Data in Clinical Oncological Research

/ Bettina Kulle Andreassen
KreftOnkologiskForum23 Play the Video 3:02
Petter Brandal

Proton vs Photon Radiotherapy for Brain Tumors in Patients with Diffuse Grade 2 and 3 Gliomas

/ Petter Brandal
KreftOnkologiskForum23 Play the Video 3:02
Kenneth Jensen

Proton Therapy for Head and Neck Cancer

/ Kenneth Jensen
KreftOnkologiskForum23 Play the Video 4:11
Giuseppe Curigliano

Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer Treatment

/ Giuseppe Curigliano
BrystkreftKreft Play the Video 4:28
Rasmus Westermann

Cancer Risk in Rheumatoid Arthritis Patients Treated with Non-TNFi bDMARDs

/ Rasmus Westermann
KreftRevmatoid artrittSCR23 Play the Video 7:28

Symptom Control in Cancer Patients: Exploring the Benefits of Olanzapine

/ Rony Dev / Sonal Admane
Kreft

HER2-Low Treatment – The Future of this Important Biomarker

/ Paolo Tarantino
BrystkreftHER2Kreft
Back to top